BioPharma Dive January 17, 2025
Jonathan Gardner

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different formulations as a single product.

Medicare’s next drug price negotiations will treat Novo Nordisk’s semaglutide as a single product, regardless of whether the metabolic disease medicine is used to treat diabetes or heart risk, and whether it is delivered by shot or pill.

Semaglutide was one of 15 drugs the Centers for Medicare and Medicaid Services selected Friday for a second round of price talks set up by the Inflation Reduction Act. Besides semaglutide, which Novo Nordisk sells as Ozempic, Rybelsus and Wegovy, the agency also chose other diabetes drugs, respiratory therapies and several cancer treatments.

CMS’ treatment...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Medicare reimbursement rates explained: Why they keep declining, and what the future holds
Medicare Drug Coverage Is Often Inadequate—Here’s Why
Medicare Drug Price Negotiations: Who really benefits?
CMS Announces Selected Drugs for 2027 Maximum Fair Price Negotiations; New Administration Issues Executive Order Affecting the IRA - Then Clarifies
GOP calls for $1.5T in cuts, much of which could come from healthcare

Share This Article